Gregg Early

About Gregg Early

GS Early has been an award-winning financial writer and editor for nearly three decades, working with many of the leading financial editors and publishers during that time. He continues to work with leading investment editors.
After working as a financial journalist for American Banker, Bond Buyer, and others covering the SEC, MSRB, Supreme Court, and various Congressional finance committees, he became Editorial Director and Vice-President of a leading financial advisory publishing firm.

It was there he built an editorial department that won dozens of SIPA Editorial Excellence Awards for quality journalism. Over the decades, Gregg has built products for several industry superstars as well as some of the brightest newcomers in the business.

His personal top beats are fintech, emerging technologies, biotech, ESG, and green tech. He also has deep experience in all facets of the markets including cryptocurrencies and derivatives. His work and his editors were regularly featured on CNBC, CNN, and Bloomberg, as well as in The New York Times, Washington Post, Wall Street Journal, Businessweek, and other media. He was also a regular moderator and speaker at MoneyShow conferences for decades.

Gregg is a graduate of James Madison University and currently resides in Charlottesville, VA.

Recent Articles

The 8 Most Reliable Blue-Chip Stocks In the Market Today

Fortunately, with these strong blue-chip stocks, buying safety doesn’t mean you’re going to miss out on growth. Here's why.

5 Online Education Stocks That Can Expand Your Horizons

These online education stocks will reap the benefits of the increasing popularity of remote education due to the novel coronavirus pandemic.

Buy Lam Research Corporation on Every Dip

If you want a core company in megatrend sector, this is it.

Apple Inc.: AAPL Stock Whistles Past the Graveyard

Apple Inc is still a remarkable company, but even AAPL stock isn't immune to the whims of the market amid global turmoil. Sell now.

INO Stock – A Cure for Cancer? Inovio Hopes So

Inovio Pharmaceuticals Inc (NASDAQ:INO) is a small biotech that could some day wipe out some of humanity's most crippling diseases. Here's why you should buy INO stock.